tiprankstipranks
Advertisement
Advertisement

RNAC Stock Latest News

Cartesian Therapeutics Shareholders Back Directors and Governance Measures
Company AnnouncementsCartesian Therapeutics Shareholders Back Directors and Governance Measures
20d ago
8K
RNAC
Reiterating Buy on Cartesian: WestGene LNP Deal Expands In Vivo Pipeline and Catalyzes Long-Term Growth
PremiumRatings
Reiterating Buy on Cartesian: WestGene LNP Deal Expands In Vivo Pipeline and Catalyzes Long-Term Growth
28d ago
RNAC
Selecta Biosciences Inc trading resumes
PremiumThe Fly
Selecta Biosciences Inc trading resumes
28d ago
RNAC
Selecta Biosciences Inc trading halted, volatility trading pause
PremiumThe Fly
Selecta Biosciences Inc trading halted, volatility trading pause
29d ago
RNAC
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance
PremiumCompany Announcements
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance
29d ago
8K
RNAC
Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures
PremiumThe FlyCartesian Therapeutics secures up to $150M financing from K2 HealthVentures
1M ago
RNAC
Cartesian Secures Major Loan Facility to Extend Runway
Premium
Company Announcements
Cartesian Secures Major Loan Facility to Extend Runway
1M ago
8K
RNAC
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Premium
The Fly
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
2M ago
RNAC
Cartesian Therapeutics management to meet with BTIG
PremiumThe Fly
Cartesian Therapeutics management to meet with BTIG
2M ago
RNAC
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
PremiumRatings
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
3M ago
RNAC
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
PremiumCompany Announcements
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
3M ago
8K
RNAC
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
PremiumCompany Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
4M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe FlyCartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
4M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
4M ago
RNAC
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
Premium
Ratings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
4M ago
RNAC
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
PremiumThe Fly
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
4M ago
RNAC
RNAC Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RNAC Upcoming Earnings Report: What to Expect?
4M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe Fly
Cartesian Therapeutics announces employment inducement grants
5M ago
RNAC
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
PremiumCompany Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
6M ago
8K
RNAC
Cartesian Therapeutics highlights recent progress, outlines 2026
PremiumThe FlyCartesian Therapeutics highlights recent progress, outlines 2026
6M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
Premium
The Fly
Cartesian Therapeutics announces employment inducement grants
6M ago
RNAC
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
7M ago
RNAC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >